Net Cash Provided by (Used in) Financing Activities of MoonLake Immunotherapeutics from 31 Mar 2021 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
MoonLake Immunotherapeutics annual and quarterly Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Mar 2021 to 31 Dec 2025.
  • MoonLake Immunotherapeutics Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $73,122,000, a 43% increase year-over-year.
  • MoonLake Immunotherapeutics annual Net Cash Provided by (Used in) Financing Activities for 2025 was $145,997,000, a 185% increase from 2024.
  • MoonLake Immunotherapeutics annual Net Cash Provided by (Used in) Financing Activities for 2024 was $51,312,000, a 89% decline from 2023.
  • MoonLake Immunotherapeutics annual Net Cash Provided by (Used in) Financing Activities for 2023 was $479,701,000, a 301% increase from 2022.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)

MoonLake Immunotherapeutics Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $145,997,000 +$94,685,000 +185% 01 Jan 2025 31 Dec 2025 10-K 25 Feb 2026 2025 FY
2024 $51,312,000 -$428,389,000 -89% 01 Jan 2024 31 Dec 2024 10-K 25 Feb 2026 2025 FY
2023 $479,701,000 +$360,008,265 +301% 01 Jan 2023 31 Dec 2023 10-K 25 Feb 2026 2025 FY
2022 $119,692,735 +$177,755,735 01 Jan 2022 31 Dec 2022 10-K 26 Feb 2025 2024 FY
2021 $58,063,000 01 Jan 2021 31 Dec 2021 10-K 17 Feb 2022 2021 FY

MoonLake Immunotherapeutics Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $73,122,000 +$22,144,000 +43% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q1 2024 $50,978,000 +$50,978,000 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q1 2023 $0 -$15,003,791 -100% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q1 2022 $15,003,791 +$73,066,791 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q1 2021 $58,063,000 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.